Experimental Therapy Halts Treatment-resistant Brain Tumors
Researchers report lab breakthrough in human cells, mouse models for high grade gliomas
The protein encoded by the Olig2 gene is present in a vast majority of gliomas. Researchers have found that using a gene therapy can halt the growth of gliomas in both human cells and mouse models. Removing the Olig2 gene stops further tumor grown. Even further, removing or eliminating the Olig2-producing cells block any type of tumor formation. “We find that elimination of dividing Olif2-expressing cells block initiation and progression of glioma in animal models and further show that Olig2 is the molecular arbiter of genetic adaptability that makes high-grade gliomas aggressive and treatment resistant,” said Qing Richard Lu, PhD, lead investigator and scientific director of the Brain Tumor Center at Cincinnati Children’s. “By finding a way to inhibit Olig2 in tumor forming cells, we were able to change that tumor cells’ makeup and sensitize them to targeting molecular treatment. This suggests a proof for stratified therapy in distinct subtypes of malignant gliomas.” To read more, click here.
Intraoperative Neurophysiology in Neurosurgery: The Essentials. 2nd Edition
Dec. 14-16, 2017; Verona, Italy
Mayo Clinic Neuroscience and Oncology Innovation Summit 2017
Dec. 14, 2017 - Dec. 16, 2017; Orlando, Fla.
43rd Annual Meeting of Louisiana Neurosurgical Society
Jan. 12, 2018 - Jan. 13, 2018; Shreveport, La.
2018 CANS Annual Meeting
Jan. 12-14, 2018; San Diego